What Neolpharma does

Neolpharma (legal entity Grupo Neolpharma, S.A. de C.V.; commercial entity Neolpharma Internacional S.A. de C.V.) is a privately held Mexican pharmaceutical group operating across the full pharmaceutical value chain — research and development, Active Pharmaceutical Ingredient (API) synthesis, finished dosage manufacturing, packaging, warehousing, and distribution. The group runs three production sites: the Vallejo II cluster in Mexico City, the NeolSyM multipurpose API plant in Ecatepec, and Neolpharma Puerto Rico in Caguas. The company commercializes a portfolio of 198 registered products and more than 300 dosage forms across 11 therapeutic classes including neuroscience, oncology, analgesics, antibiotics, cardiovascular, dermatology, endocrinology, gastroenterology, pulmonology, rheumatology, vitamins, hormonal, and gynecological products. A subset of branded and specialty products includes Transkrip, an epigenetic therapy for cancer developed under a patented licensing arrangement (MX 270322 B) with UNAM and INCAN.

Beyond its own-label business, Neolpharma operates as a Contract Development and Manufacturing Organization (CDMO) offering manufacturing, QA services, technology transfer, bioequivalence studies, analytical and stability testing, packaging, warehousing, and distribution to third-party pharmaceutical clients. Notable CDMO engagements include a bioequivalence study and site transfer from Viatris to Neolpharma for a Pfizer product. The company is led by President & CEO Efrén Ocampo and reports 1,001–5,000 employees across the group.

The business model combines product sales (one-time revenue per unit) with professional services revenue from contract manufacturing. GTM motion is sales-led via direct engagement with pharmaceutical companies and healthcare providers, with international distribution supported by top-tier regulatory certifications: FDA, EMA, ANVISA, KFDA, MHRA, and DEA. R&D is funded at 10% of total sales and supported by three internal centers — CedProf, Cidat, and CIM — alongside translational partnerships with Mexican National Institutes of Health, UNAM, and CINVESTAV.

Name

Neolpharma

Legal name

Neolpharma Internacional S.A. de C.V.

Website

https://neolpharma.com

Company type

Private

Founded year

1993

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Neolpharma is a privately held Mexican pharmaceutical group that researches, develops, manufactures, and distributes generic and specialty medicines across 11 therapeutic classes, and operates as a CDMO serving global pharma clients from three production sites in Mexico and Puerto Rico.

Ownership category

akta.pro rank

Product category

Generic Pharmaceutical Manufacturing

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Specialty Pharmacy & Biologics Distribution (CRAOAHAD)

akta.pro secondary industries

Controlled Substances & Compliance-Focused Pharmaceutical Distributors (HLAIAJAN), Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)

Keywords

• Pharmaceutical manufacturing
• Generic medicines
• Contract development manufacturing
• Active pharmaceutical ingredients
• Pharmaceutical distribution

Headquarters

HQ city

Ciudad De León

HQ country

Mexico

HQ region

Latin America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales: Neolpharma Group manufactures and commercializes pharmaceutical products across 198 registered products and more than 300 dosage forms in 11 therapeutic classes including neuroscience, oncology, analgesics, antibiotics, cardiovascular, dermatology, endocrinology, gastroenterology, pulmonology, rheumatology, vitamins, hormonal, and gynecological products.
2. Contract Manufacturing Services: Full-service CDMO offering manufacturing, QA services, technology transfer assistance, analysis and stability testing, packaging, warehousing, and distribution services to pharmaceutical companies.
3. API Manufacturing: NeolSyM manufactures Active Pharmaceutical Ingredients including Methylphenidate Hydrochloride, Phenytoin, Sodium Phenytoin, and Bezafibrate, with current development of Celecoxib and Magnesium Valproate.
4. Technology Transfer and Site Transfer Services: Supporting manufacturing site transfers for pharmaceutical products through bioequivalence studies, such as the Pfizer site transfer from Viatris to Neolpharma.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels1 record

Core offering

Neolpharma researches, develops, manufactures, and distributes generic and specialty pharmaceutical products across 11 therapeutic classes (neuroscience, oncology, analgesics, antibiotics, cardiovascular, dermatology, endocrinology, gastroenterology, pulmonology, rheumatology, vitamins, hormonal, gynecology) through a portfolio of 198 registered products and 300+ dosage forms. The group also operates as a Contract Development and Manufacturing Organization (CDMO), offering API synthesis (NeolSyM), solid oral and injectable manufacturing, QA, technology transfer, analytical and stability testing, packaging, warehousing, and distribution services to other pharmaceutical companies from three production sites in Mexico City, Ecatepec, and Puerto Rico.

Product overview

Neolpharma (Grupo Farmacéutico) is a pharmaceutical manufacturing group with over 30 years of experience, comprising a portfolio of 198 registered products and more than 300 dosage forms. The company's product ecosystem includes three main production facilities: Neolpharma Vallejo II in Mexico City (producing solids, liquids, injectables, effervescents, ampoules, soft gelatin capsules, and parenterals), the NeolSyM plant in Ecatepec specializing in active pharmaceutical ingredients (APIs including Methylphenidate Hydrochloride, Phenytoin, Sodium Phenytoin, Bezafibrate), and Neolpharma Puerto Rico with 5.2 billion SDU annual capacity. The portfolio spans 11 therapeutic classes (neuroscience, oncology, analgesics, antibiotics, cardiovascular, dermatology, endocrinology, gastroenterology, pulmonology, rheumatology, vitamins, hormonal, gynecology) including branded products like Transkrip (epigenetic therapy for cancer). Complementing manufacturing, the company offers integrated services including QA services, technology transfer assistance, analysis and stability testing, packaging, warehousing, and distribution. Research and development operations are supported by three centers (CedProf, Cidat, CIM) funded by 10% of total sales.

Differentiator

Problem solved

Functional benefit

Products and services

• Transkrip An epigenetic therapy medication indicated for cervical, ovarian, breast, and other tumors that enhances chemotherapy effectiveness, developed through partnership between UNAM, INCAN, and Psicofarma and protected under patent MX/a/2007/002871 (granted as MX 270322 B).
• Neolpharma Product Portfolio Commercial portfolio of 198 registered pharmaceutical products and more than 300 dosage forms spanning 11 therapeutic classes including neuroscience, oncology, analgesics, antibiotics, cardiovascular, dermatology, endocrinology, gastroenterology, pulmonology, rheumatology, vitamins, hormonal, and gynecology; encompasses OTC, generic, and cardio-metabolic health products marketed across Mexico, Latin America, USA, and global export markets.
• NeolSyM Active Pharmaceutical Ingredients (APIs)
• Neolpharma Manufacturing Services
• QA Services
• Technology Transfer Assistance
• Analysis and Stability Services
• Packaging Services
• Warehousing Services
• Distribution Services

Quantifiable outcome

• 10% of total sales invested in R&D enabling continuous product development and innovation
• +2 more outcomes

Named customers2 records

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• UNAM (Universidad Nacional Autónoma de México)coreStrategic or Co-development Partner · 1 January 2009Landmark partnership between UNAM, INCAN, and Psicofarma resulted in Transkrip, an epigenetic therapy that enhances chemotherapy. UNAM provided research and academic expertise for drug development. This partnership exemplifies translational medicine in Mexico.
• INCAN (Instituto Nacional de Cancerología)coreStrategic or Co-development Partner · 1 January 2009Partnership with UNAM and Psicofarma for development of Transkrip epigenetic therapy for cancer treatment. INCAN provided clinical research expertise and patient studies.
• CINVESTAV (Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional)minorStrategic or Co-development PartnerCINVESTAV endorses the Neolpharma Award to Innovation in Technology, supporting scientific and technological research development in Mexico.
• Colegio de MéxicominorStrategic or Co-development PartnerCollaboration with Colegio de México to sponsor the Victor L. Urquidi Award for economic research and Gustavo Cabrera Acevedo Award for urban and environmental thesis research.
• Mexican National Institutes of HealthcoreStrategic or Co-development PartnerResearch backed by prestigious institutions including Instituto Nacional de Neurología y Neurocirugía, Instituto de Investigaciones Biomédicas de la UNAM, Instituto Nacional de Cancerología, Hospital Infantil de México, and Instituto Nacional de Rehabilitación for development of treatments for chronic diseases.
• CIDAT (Centro de Farmacovigilancia, Investigación y Detección Temprana)coreTechnology or IntegrationPharmacovigilance, Research and Early Detection Center with agreements for conducting Bioequivalence and Bioavailability studies. Certified by Ministry of Health for drug product assessment.
• CedProf (Centro de Investigación y Desarrollo para Productos Diferenciados)coreTechnology or IntegrationInternal R&D center developing differentiated pharmaceutical forms to improve patient treatment adherence.
• CIM (Centro de Información de Medicamentos)coreTechnology or IntegrationDrug Information Centre with comprehensive database containing updated studies on each drug, providing specialists with pharmacokinetics, pharmacodynamics, and therapeutic indication information.

Scale indicators5 records

Recent moves8 records

Expansion highlights6 records

Broad incumbents

• Aurobindo Pharma: India-based global generics and API manufacturer with significant US and emerging-market exposure. Comparable to Neolpharma as a broad-portfolio generics exporter competing in many of the same therapeutic and regulatory channels.
• Teva Pharmaceutical Industries: World's largest generics manufacturer with broad API, generic, and specialty operations and extensive US/EU regulatory infrastructure. Comparable to Neolpharma on portfolio breadth and export-driven generics distribution, though at vastly greater scale.
• Patheon (Thermo Fisher Scientific): Global pharmaceutical development and manufacturing services franchise within Thermo Fisher, offering API and dose-form CDMO at scale. Comparable as a CDMO competitor and potential partner for technology transfers similar to Neolpharma's Pfizer engagement.
• Catalent: Global CDMO providing development, manufacturing, and packaging services to pharma and biologics sponsors. Comparable to Neolpharma on the CDMO side of the business, though at much larger scale and with broader modality coverage.
• Siegfried Holding: Swiss-listed CDMO with API and finished-dose manufacturing for global pharma customers. Comparable to Neolpharma on the integrated API-to-dose CDMO model, particularly for technology-transfer and small-to-mid-volume mandates.

Direct peers

• Laboratorios Liomont: Mexican pharmaceutical manufacturer with a broad generics and specialty portfolio plus in-house R&D. Directly comparable to Neolpharma's domestic manufacturing-plus-innovation model and Latin American market focus.
• Grupo Pisa: One of Mexico's largest integrated pharmaceutical groups, with manufacturing, distribution, and hospital-supply operations. Highly comparable to Neolpharma given similar Mexican footprint, broad product portfolio, and exposure to both branded and generic categories.
• Eurofarma: Latin America's largest privately held pharmaceutical company, operating generics, branded, and CDMO businesses across the region. Comparable to Neolpharma as a regional, vertically integrated pharma group pursuing export-led growth.
• Genomma Lab: Mexican pharmaceutical company with a broad OTC, personal care, and generics portfolio across Latin America. Comparable to Neolpharma in Mexican origin, therapeutic breadth, and reliance on distribution-driven scale.

Regional players

• Laboratorios Cinfa: Spain's leading generics manufacturer by units sold, with broad therapeutic coverage and a CDMO-adjacent posture. Comparable in operating model (broad generics portfolio) though it competes in European rather than Latin American channels.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/GrupoNeolpharma

Compliance11 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries4 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Neolpharma